Viewing nowValsate Tablet 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
Daewon Biotech Co., Ltd.

MFDS item code 202001766 · Approved 2020.03.13 · Insurance code 057600640
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used to control essential hypertension. It is also effective in patients with heart failure who have intolerance to ACE inhibitors and are classified as NYHA class II to IV. It helps to reduce the risk of mortality in clinically stable patients with left ventricular failure or dysfunction following myocardial infarction. Therefore, it is used for managing hypertension, treating heart failure, and reducing mortality after myocardial infarction.
1. Essential hypertension Take with water during or between meals. If possible, take it at the same time each day (e.g., in the morning). Adults: Regardless of sex or race, oral valsartan 80 mg once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. Older adults (aged 75 years and older): Initiate treatment with 40 mg of this medicine once daily. Patients with renal impairment: Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. Patients with renal impairment: Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. Patients with renal impairment: Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily, and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily; this may be increased to 80 mg or 160 mg per dose. When coadministered with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily, followed over several weeks by titration, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is at least 10 mL/min; however, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Children: The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. Children: The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.
This drug can cause serious harm or death to the fetus and newborn when taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. This drug should not be used in women with a history of allergic reactions, those who are pregnant or may become pregnant, patients with severe liver or kidney disorders, and certain hereditary angioedema patients. Elderly patients or those with hyperkalemia, mild to moderate liver disorders, valvular heart disease, or ischemic heart disease should use this drug with caution, and watch for hypotension or changes in renal function. While taking this drug, side effects such as headache, dizziness, fatigue, cough, diarrhea, and nausea may occur, and rarely, serious adverse reactions such as angioedema, hepatitis, renal failure, or hypoglycemia may develop, so if symptoms appear, medical consultation should be sought immediately. This drug can cause a rapid drop in blood pressure; if hypotension is experienced, it should be stopped immediately, and appropriate treatment should be received, particularly in patients undergoing dialysis or taking diuretics. Due to the risk of hyperkalemia, serum potassium levels should be frequently monitored when used alongside potassium supplements or potassium-sparing diuretics. When taken with other antihypertensives or non-steroidal anti-inflammatory drugs (NSAIDs), the hypotensive effect may be reduced or renal function may be affected, so consultation with a healthcare professional is recommended. Women who are pregnant or breastfeeding are advised not to use this drug, and if it must be taken while breastfeeding, discontinuation of breastfeeding is preferable. Safety has not been established in children and adolescents; therefore, use is not recommended. In case of overdose, severe hypotension, decreased consciousness, shock, etc., may occur, so immediate medical attention should be sought. This drug should be stored out of reach of children, and it is safer not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly closed container to prevent air and moisture from entering, and it is advisable to keep it in a cool place below 30 degrees Celsius, away from direct sunlight or high temperatures.
Oval film-coated tablet orange with a gray tint
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Daewon Biotech Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.